{
    "clinical_study": {
        "@rank": "159761", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Tolvaptan", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Hyponatremia is a condition in which there is a low sodium level in the blood. Individuals\n      with cirrhosis may develop low blood sodium as a complication of their liver disease.  In\n      these patients, the presence of low blood sodium may exacerbate other complications such as\n      encephalopathy, resulting in confusion, drowsiness, or coma. It may also affect the ability\n      of the body to fight infection.  In certain cases, cirrhotic patients may be hospitalized\n      for the treatment of their low blood sodium.\n\n      The drug tolvaptan is currently FDA approved for the treatment of hyponatremia in patients\n      with cirrhosis. Although it has been shown to increase the sodium level, the clinical trials\n      that led to its approval did not otherwise assess clinical benefit of the drug.\n\n      This study is designed to determine whether patients with cirrhosis derive a clinical\n      benefit when they receive tolvaptan for the treatment of hyponatremia within 2 days of\n      admission. Specifically, whether it is associated with shortened length of stay and\n      improvement in other complications of cirrhosis."
        }, 
        "brief_title": "Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyponatremia", 
        "condition_browse": {
            "mesh_term": [
                "Hyponatremia", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hyponatremia is a condition in which there is a low sodium level in the blood. Individuals\n      with cirrhosis may develop low blood sodium as a complication of their liver disease.  In\n      these patients, the presence of low blood sodium may exacerbate other complications such as\n      encephalopathy, resulting in confusion, drowsiness, or coma. It may also affect the ability\n      of the body to fight infection.  In certain cases, cirrhotic patients may be hospitalized\n      for the treatment of their low blood sodium.\n\n      The drug tolvaptan is currently FDA approved for the treatment of hyponatremia in patients\n      with cirrhosis. Although it has been shown to increase the sodium level, the clinical trials\n      that led to its approval did not otherwise assess clinical benefit of the drug.\n\n      This study is designed to determine whether patients with cirrhosis derive a clinical\n      benefit when they receive tolvaptan for the treatment of hyponatremia within 2 days of\n      admission. Specifically, whether it is associated with shortened length of stay and\n      improvement in other complications of cirrhosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cirrhosis\n\n          -  Screening within 24 hours of admission\n\n          -  Na level less than 130mEq/L\n\n          -  Presence of fluid overload with either history of ascites or edema\n\n          -  Cr < 2.0mg/dl\n\n          -  Planned length of stay after randomization of at least 24 hours\n\n          -  Anticipated survival of at least 8 days\n\n          -  Ability to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Hospitalization greater than 24 hours at screening\n\n          -  Depletional hyponatremia\n\n          -  Hyponatremia due to hyperglycemia\n\n          -  Acute and transient hyponatremia associated with head trauma or post-operative states\n\n          -  Hyponatremia due to primary polydipsia, adrenal insufficiency, or hypothyroidism\n\n          -  Urgent need for treatment of hyponatremia with saline or hypertonic saline\n\n          -  Treatment with demeclocycline, lithium chloride, and urea\n\n          -  Cr greater than 2.0mg/dl\n\n          -  Stage 3 or 4 hepatic encephalopathy\n\n          -  Inability to provide informed consent\n\n          -  Planned discharge within 24 hours\n\n          -  Anticipated survival less than 8 days\n\n          -  GI bleeding within one month of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890694", 
            "org_study_id": "10-02496"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tolvaptan", 
                "description": "15 mg once daily", 
                "intervention_name": "Tolvaptan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "15 mg once daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Tolvaptan"
                ], 
                "description": "The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.", 
                "intervention_name": "Hepatic Encephalopathy Assessment", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Tolvaptan"
                ], 
                "description": "The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge", 
                "intervention_name": "Quality of Life Assessment", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Tolvaptan"
                ], 
                "description": "Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.", 
                "intervention_name": "Vital signs", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Tolvaptan"
                ], 
                "description": "Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.", 
                "intervention_name": "Blood laboratory tests", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Tolvaptan"
                ], 
                "description": "Ascites will be assessed at every visit.", 
                "intervention_name": "Ascites Evaluation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Tolvaptan"
                ], 
                "description": "Edema will be assessed at every visit.", 
                "intervention_name": "Edema", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hyponatremia", 
            "Dilutional Hyponatremia", 
            "Euvolemic Hyponatremia", 
            "Hypervolemic Hyponatremia", 
            "Fluid Restriction", 
            "Tolvaptan"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "email": "samuel.sigal@nyumc.org", 
                "last_name": "Samuel Sigal, MD", 
                "phone": "212-263-3643"
            }, 
            "contact_backup": {
                "email": "neerav.shah@nyumc.org", 
                "last_name": "Neerav Shah, MD", 
                "phone": "212-263-3643"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "NYU Langone Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia", 
        "overall_contact": {
            "email": "samuel.sigal@nyumc.org", 
            "last_name": "Samuel Sigal, MD", 
            "phone": "212-263-3643"
        }, 
        "overall_contact_backup": {
            "email": "lilian.salinas@nyumc.org", 
            "last_name": "Lilian Salinas, MA", 
            "phone": "212-263-3643"
        }, 
        "overall_official": {
            "affiliation": "NYU School of Medicine", 
            "last_name": "Samuel Sigal, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Length of Hospital Stay", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890694"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline of Hepatic Encephalopathy", 
                "measure": "Severity of Hepatic Encephalopathy", 
                "safety_issue": "No", 
                "time_frame": "Day 2"
            }, 
            {
                "description": "Change from baseline of Hepatic Encephalopathy", 
                "measure": "Severity of Hepatic Encephalopathy", 
                "safety_issue": "No", 
                "time_frame": "Day 4"
            }, 
            {
                "description": "Change from baseline of Hepatic Encephalopathy", 
                "measure": "Severity of Hepatic Encephalopathy", 
                "safety_issue": "No", 
                "time_frame": "Day 6"
            }, 
            {
                "description": "Change from baseline of Hepatic Encephalopathy", 
                "measure": "Severity of Hepatic Encephalopathy", 
                "safety_issue": "No", 
                "time_frame": "Day 8"
            }, 
            {
                "description": "Change from baseline of Hepatic Encephalopathy", 
                "measure": "Severity of Hepatic Encephalopathy", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "Change from baseline of Hepatic Encephalopathy", 
                "measure": "Severity of Hepatic Encephalopathy", 
                "safety_issue": "No", 
                "time_frame": "Week 1-4 Post-discharge"
            }, 
            {
                "description": "Change from baseline of Hepatic Encephalopathy", 
                "measure": "Severity of Hepatic Encephalopathy", 
                "safety_issue": "No", 
                "time_frame": "Months 2-6 post-discharge"
            }, 
            {
                "description": "Improved control of ascites", 
                "measure": "Ascites", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Post-discharge (6 months)"
            }, 
            {
                "description": "Improved renal function from baseline", 
                "measure": "Renal function [BUN and creatinine laboratory results]", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Post-discharge (6 months)"
            }, 
            {
                "description": "Lower readmission rate", 
                "measure": "Hospital Readmission Rate", 
                "safety_issue": "No", 
                "time_frame": "Post-Discharge (6 months)"
            }, 
            {
                "description": "Improved chances of survival when receiving Tolvaptan vs. standard of care", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "Post-discharge (6 months)"
            }, 
            {
                "description": "Improved neutrophil function from baseline", 
                "measure": "Neutrophil function [results from the assay of neutrophils]", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Post-discharge (6 months)"
            }, 
            {
                "description": "Improved ability to tolerate diuretic therapy, as evidenced by reduced adverse events to diuretic therapy and reduced risk of re-hospitalization.", 
                "measure": "Tolerability of diuretic therapy", 
                "safety_issue": "No", 
                "time_frame": "Day 1 until Discharge (participants will be followed for the duration of hospital stay, an expected average of 2 weeks)"
            }
        ], 
        "source": "New York University School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka America Pharmaceutical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "New York University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}